SPARC196.80

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health
₹ CrorePeersSTARSHILPAMEDSUPRIYATHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹6,386 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation12.512.410.2
+ Finance Costs1.79.034.1
+ Interest Income-25.5-0.7-10.3
+ Unrealised FX (Gain) / Loss2.10.97.4
+ Other Non-cash Items1.5-0.0-0.2
Changes in Working Capital
+ Trade Receivables — Current15.2-0.48.3
+ Other Financial Assets — Current-3.2-1.10.0
+ Other Current Assets-63.13.4-1,858.6
+ Trade Payables — Current-5.9-29.3-18.2
+ Other Current Liabilities22.7-16.9-8.0
+ Provisions — Current3.8-3.611.9
Cash from Operating Activities
Profit Before Tax (per I/S)-386.8-342.81,553.01,584.2
+ Total Adjustments (incl. Working Capital)-38.3-26.3-1,823.4
Cash from Operations (pre-tax)-425.1-369.1-270.4
+ Income Taxes Paid4.1-8.8-31.6
Cash from Operating Activities-429.2-360.3-238.8
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)26.510.323.8
+ Disp of Fixed Assets0.50.60.3
+ Disp of Investment Property284.22.90.0
+ Interest Received — Investing22.414.60.0
+ Other Inflows / (Outflows) — Investing111.0150.00.0
Cash from Investing Activities391.5157.7-23.5
Cash from Financing Activities
+ Proceeds from Borrowings64.4580.22,115.8
+ Repayment of Borrowings17.5369.01,817.9
+ Payment of Lease Liabilities2.93.52.4
+ Interest Paid1.68.434.2
Cash from Financing Activities42.4199.3261.4
Net Changes in Cash (pre-FX)4.8-3.4-0.9
+ Effect of FX Rate Changes on Cash0.00.00.1
Net Changes in Cash4.8-3.4-0.8
Closing Cash5.32.0
Reference Items
EBITDA-402.1-323.11,598.81,616.8
EBITDA Margin %-532.23-450.2485.0884.68
Free Cash Flow (CFO − Capex)-455.7-370.6-262.6-262.6
Free Cash Flow to Equity-167.91.1
Free Cash Flow per Basic Share-14.04-11.42-8.09-8.09
Cash Flow to Net Income1.111.05-0.15
Cash Paid for Taxes4.1-8.8-31.6
Cash Paid for Interest1.68.434.2
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.